Ensuring robust lyophilization scale-up
Presentation provides new data regarding the mechanism of the ControLyo Technology.
SP Scientific announces the on-demand popular webinar by Jake Luoma of Genentech that discusses how controlled nucleation has emerged as a technology that promises improvements in lyophilization process throughput and consistency.
In this presentation, Mr Luoma examines the benefits of the technology for high fill-volume configurations and presents new data regarding the mechanism of the ControLyo Technology. The presentation shows how gaining a more complete understanding of the mechanism of nucleation using ControLyo Technology ensures more robust freezing when scaling from the lab to commercial-scale freeze dryers.
Traditionally in lyophilization cycles, the freezing process is uncontrolled because of the random nature of the nucleation or crystal-forming process within individual vials and across vials in a freeze dryer chamber. SP Scientific's proprietary ControLyo technology, utilizes pressurization to induce nucleation while maintaining the temperature to within 1 °C of a product’s freezing point and at the same time minimizes the supercooling effect. This produces lowered product resistance with resulting benefits that include improved product uniformity, quality and yield, and depending on formulation a reduction of cycle times by as much as 40%. In contrast to other controlled nucleation techniques, ControLyo Technology process does not introduce any foreign elements which could potentially become a carrier for micro-organisms being introduced into the product vials during the freezing process.
Jacob (Jake) Luoma has been an engineer at Genentech since 2012. After he graduated from the University of Colorado Boulder with a BS in Chemical and Biological Engineering, he joined the Genentech Process Development Rotation Program. Jake then joined the Pharmaceutical Processing and Technology Development group. There, he works on a team which develops pharmaceutical drug product manufacturing processes and technologies on the pilot scale and conducts technology transfers to implement on the manufacturing scale.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.